FDA-Approved Breast Cancer Drug Added to NCCN Treatment Guidelines

Celcuity Inc.'s newly FDA-approved drug, REVTORPYK™ (gedatolisib), has been incorporated into the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology. It is now a preferred Category 1 second-line or subsequent-line therapy for patients with HR+/HER2- breast cancer who have progressed on prior endocrine therapy, offering a new treatment option.